Strengthening strategic partnerships and expanding client base through North America-Asia manufacturing hubs ■  Targeting ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

A ripple effect of the NIH's slashed 2026 budget will be felt throughout the biopharma ecosystem. Young companies must act ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

The FDA has denied that it plans to combine the Center for Drug Evaluation and Research and Center for Biologics Evaluation ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

In 17 identical letters posted to his Truth Social account, the president said companies must lower their prices or the ...

In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...